ACTINIUM PHARMACEUTICALS, INC. — Net Income by Fiscal Year
25 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/15d4ddbd-940d-4011-91d9-bf31f4e7c996/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-33.9M | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-036504 |
| FY 2024 | $-38.2M | 2024-01-01 – 2024-12-31 | evidence 0001213900-25-026371 |
| FY 2023 | $-48.8M | 2023-01-01 – 2023-12-31 | evidence 0001213900-24-028038 |
| FY 2022 | $-33.0M | 2022-01-01 – 2022-12-31 | evidence 0001213900-23-025597 |
| FY 2021 | $-24.8M | 2021-01-01 – 2021-12-31 | evidence 0001213900-22-015208 |
| FY 2020 | $-22.2M | 2020-01-01 – 2020-12-31 | evidence 0001213900-21-019297 |
| FY 2019 | $-21.9M | 2019-01-01 – 2019-12-31 | evidence 0001213900-21-019297 |
| FY 2018 | $-23.7M | 2018-01-01 – 2018-12-31 | evidence 0001213900-19-004269 |
| FY 2017 | $-26.6M | 2017-01-01 – 2017-12-31 | evidence 0001213900-18-003091 |
| FY 2016 | $-24.3M | 2016-01-01 – 2016-12-31 | evidence 0001213900-17-002461 |
| FY 2015 | $-21.0M | 2015-01-01 – 2015-12-31 | evidence 0001213900-16-011534 |
| FY 2014 | $-24.7M | 2014-01-01 – 2014-12-31 | evidence 0001213900-15-001800 |
| FY 2013 | $-83.2M | 2000-06-14 – 2014-03-31 | evidence 0001213900-14-003153 |
| FY 2012 | $-56.4M | 2000-06-14 – 2013-03-31 | evidence 0001213900-13-002615 |
| FY 2011 | $-3.4M | 2011-01-01 – 2011-12-31 | evidence 0001213900-13-001417 |
| FY 2010 | $-467.3k | 2010-01-01 – 2010-12-31 | evidence 0001213900-13-001417 |
| FY 2009 | $-3.4M | 2009-01-01 – 2009-12-31 | evidence 0001213900-13-001417 |
| FY 2008 | $-5.6M | 2008-01-01 – 2008-12-31 | evidence 0001213900-13-001417 |
| FY 2007 | $-5.6M | 2007-01-01 – 2007-12-31 | evidence 0001213900-13-001417 |
| FY 2006 | $-6.1M | 2006-01-01 – 2006-12-31 | evidence 0001213900-13-001417 |
| FY 2005 | $-4.6M | 2005-01-01 – 2005-12-31 | evidence 0001213900-13-001417 |
| FY 2004 | $-5.7M | 2004-01-01 – 2004-12-31 | evidence 0001213900-13-001417 |
| FY 2003 | $-3.5M | 2003-01-01 – 2003-12-31 | evidence 0001213900-13-001417 |
| FY 2002 | $-3.2M | 2002-01-01 – 2002-12-31 | evidence 0001213900-13-001417 |
| FY 2001 | $-5.1M | 2001-01-01 – 2001-12-31 | evidence 0001213900-13-001417 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ACTINIUM PHARMACEUTICALS, INC. — all facts · Revenue · Operating Income